Atlas of Cancer Signalling Network: A systems biology resource for integrative analysis of cancer data with Google Maps

Oncogenesis

Volumn 4, Issue , 2015, Pages

  Kuperstein, I ^a,b,c   Bonnet, E ^a,b,c   Nguyen, H A ^a,b,c   Cohen, D ^a,b,c   Viara, E ^d   Grieco, L ^a,b,c,e,f,g   Fourquet, S ^a,b,c   Calzone, L ^a,b,c   Russo, C ^a,b,c   Kondratova, M ^a,b,c   Dutreix, M ^a,h   Barillot, E ^a,b,c   Zinovyev, A ^a,b,c  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d Sysra   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f CNRS   (France)

^g INSERM   (France)

^h Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTOME;

APOPTOSIS; ARTICLE; ATLAS OF CANCER SIGNALLING NETWORK; BREAST CANCER; CANCER GROWTH; CANCER RESEARCH; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COPY NUMBER VARIATION; DNA REPAIR; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE DOSAGE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HOMOLOGOUS RECOMBINATION; HUMAN; INTERNET; LUNG CANCER; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MUTATION RATE; NEOPLASM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; RNA INTERFERENCE; SEMANTICS; SYSTEMS BIOLOGY; TREATMENT RESPONSE;

EID: 84937679407     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.19     Document Type: Article

References (80)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Prasasya RD, Tian D, Kreeger PK. Analysis of cancer signaling networks by systems biology to develop therapies. Semin Cancer Biol 2012; 21: 200-206.
3. Ooi HS, Schneider G, Lim TT, Chan YL, Eisenhaber B, Eisenhaber F. Biomolecular pathway databases. Methods Mol Biol 2010; 609: 129-144.
4. Koutsogiannouli E, Papavassiliou AG, Papanikolaou NA. Complexity in cancer biology: is systems biology the answer? Cancer Med 2013; 2: 164-177.
5. Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resist Updat 2012; 15: 249-257.
6. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nat Rev Cancer 2012; 12: 411-424.
7. Le Novere N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A et al. The Systems Biology Graphical Notation. Nat Biotechnol 2009; 27: 735-741.
8. Kitano H, Funahashi A, Matsuoka Y, Oda K. Using process diagrams for the graphical representation of biological networks. Nat Biotechnol 2005; 23: 961-966.
9. Nagasaki M, Saito A, Jeong E, Li C, Kojima K, Ikeda E et al. Cell illustrator 4.0: a computational platform for systems biology. Stud Health Technol Inform 2011; 162: 160-181.
10. Calzone L, Gelay A, Zinovyev A, Radvanyi F, Barillot E. A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 2008; 4: 173.
11. Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol 2010; 6: 453.
12. Fink MY, Pincas H, Choi SG, Nudelman G, Sealfon SC. Research resource: Gonadotropin-releasing hormone receptor-mediated signaling network in LbetaT2 cells: a pathway-based web-Accessible knowledgebase. Mol Endocrinol 2010; 24: 1863-1871.
13. Grieco L, Calzone L, Bernard-Pierrot I, Radvanyi F, Kahn-Perles B, Thieffry D. Integrative modelling of the influence of MAPK network on cancer cell fate decision. PLoS Comput Biol 2013; 9: e1003286.
14. Oda K, Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2006; 2: 2006.0015.
15. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005.0010.
16. Pathak RK, Taj G, Pandey D, Arora S, Kumar A. Modeling of the MAPK machinery activation in response to various abiotic and biotic stresses in plants by a system biology approach. Bioinformation 2013; 9: 443-449.
17. Hower V, Mendes P, Torti FM, Laubenbacher R, Akman S, Shulaev V et al. A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst 2009; 5: 422-443.
18. Cavalieri D, Rivero D, Beltrame L, Buschow SI, Calura E, Rizzetto L et al. DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome Res 2010; 6: 10.
19. Patil S, Pincas H, Seto J, Nudelman G, Nudelman I, Sealfon SC. Signaling network of dendritic cells in response to pathogens: a community-input supported knowledgebase. BMC Syst Biol 2010; 4: 137.
20. Autiero I, Costantini S, Colonna G. Modeling of the bacterial mechanism of methicillin-resistance by a systems biology approach. PLoS ONE 2009; 4: e6226.
21. Dampier W, Tozeren A. Signaling perturbations induced by invading H. pylori proteins in the host epithelial cells: a mathematical modeling approach. J Theor Biol 2007; 248: 130-144.
22. Mizuno S, Iijima R, Ogishima S, Kikuchi M, Matsuoka Y, Ghosh S et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol 2012; 6: 52.
23. Wu G, Zhu L, Dent JE, Nardini C. A comprehensive molecular interaction map for rheumatoid arthritis. PLoS ONE 2010; 5: e10137.
24. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S et al. A map of human cancer signaling. Mol Syst Biol 2007; 3: 152.
25. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T et al. PID: the Pathway Interaction Database. Nucleic Acids Res 2009; 37: D674-D679.
26. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 2010; 39: D685-D690.
27. Curtin NJ. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 2013; 169: 1745-1765.
28. Du HN. Transcription, DNA damage and beyond: the roles of histone ubiquitination and deubiquitination. Curr Protein Pept Sci 2012; 13: 447-466.
29. Horowitz JC, Rogers DS, Sharma V, Vittal R, White ES, Cui Z et al. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 2007; 19: 761-771.
30. Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K et al. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 2011; 71: 4720-4731.
31. Santi SA, Lee H. Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells. PLoS ONE 2011; 6: e14614.
32. Khan KH, Blanco-Codesido M, Molife LR. Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol Hematol 2014; 90: 200-219.
33. Lockshin RA, Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007; 11: 1214-1224.
34. Ishibashi Y, Kohyama-Koganeya A, Hirabayashi Y. New insights on glucosylated lipids: metabolism and functions. Biochim Biophys Acta 2013; 1831: 1475-1485.
35. Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development 2012; 139: 3471-3486.
36. Kuperstein I, Cohen DP, Pook S, Viara E, Calzone L, Barillot E et al. NaviCell: a web-based environment for navigation, curation and maintenance of large molecular interaction maps. BMC. Syst Biol 2013; 7: 100.
37. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G et al. The Reactome pathway knowledgebase. Nucleic Acids Res 2013; 42: D472-D477.
38. Kanehisa M. The KEGG database. Novartis Found Symp 2002; 247: 91-101 discussion 3, 19-28, 244-252.
39. Bonnet E, Calzone L, Rovera D, Stoll G, Barillot E, Zinovyev A. BiNoM 2.0, a Cytoscape plugin for accessing and analyzing pathways using standard systems biology formats. BMC. Syst Biol 2012; 7: 18.
40. Zinovyev A, Viara E, Calzone L, Barillot E. BiNoM: a Cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics 2008; 24: 876-877.
41. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558.
42. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2014; 43: D805-D811.
43. Bonnet E, Viara E, Kuperstein I, Calzone L, Cohen DPA, Barillot E, Zinovyev A. NaviCell Web Service for network-based data visualization. Nucleic Acids Res 2015; 43: W560-W565.
44. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
45. Berns K, Bernards R. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat 2012; 15: 268-275.
46. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006; 26: 9377-9386.
47. Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapyassociated apoptosis in gastric cancer cells. Gastric Cancer 2013; 16: 100-110.
48. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
49. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-3637.
50. Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 2013; 49: 1725-1740.
51. Su E, Han X, Jiang G. The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia. Tumori 2011; 96: 659-666.
52. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005; 11: 2606-2611.
53. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006; 66: 2202-2209.
54. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the upregulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 2010; 128: 657-666.
55. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005; 25: 8108-8125.
56. Pohl M, Radacz Y, Pawlik N, Schoeneck A, Baldus SE, Munding J et al. SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells. Anticancer Res 2010; 30: 2603-2613.
57. Malkoski SP, Wang XJ. Two sides of the story? Smad4 loss in pancreatic cancer versus head-And-neck cancer. FEBS Lett 2012; 586: 1984-1992.
58. Sun J, He H, Pillai S, Xiong Y, Challa S, Xu L et al. GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion. J Biol Chem 2013; 288: 36971-36982.
59. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013; 499: 214-218.
60. Cirillo N. Merging experimental data and in silico analysis: a systems-level approach to autoimmune disease and cancer. Expert Rev Clin Immunol 2012; 8: 361-372.
61. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
62. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
63. Vergara D, Simeone P, del Boccio P, Toto C, Pieragostino D, Tinelli A et al. Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Mol Biosyst 2013; 9: 1127-1138.
64. Sims AH, Larionov AA, Harrison DJ, Katz E. Use of microarray analysis to investigate EMT gene signatures. Methods Mol Biol 2013; 1046: 85-95.
65. Bouvard D, Pouwels J, De Franceschi N, Ivaska J. Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol 2013; 14: 430-442.
66. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2011; 40: D261-D270.
67. Dy GK. The role of focal adhesion kinase in lung cancer. Anticancer Agents Med Chem 2013; 13: 581-583.
68. Barillot E, Calzone L, Hupe P, Vert J-P, Zinovyev A. Computational Systems Biology of Cancer. CRC Press, Boca Raton, FL, USA, 2012.
69. Weinberg RA. The Biology of Cancer, 2nd edn. Garland Science, New York, US, 2013.
70. Matsuoka Y, Ghosh S, Kikuchi N, Kitano H. Payao: a community platform for SBML pathway model curation. Bioinformatics 2010; 26: 1381-1383.
71. Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, Evelo CT et al. Wiki-Pathways: building research communities on biological pathways. Nucleic Acids Res 2012; 40: D1301-D1307.
72. Huang YF, Yeh HY, Soo VW. Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation. BMC Med Genomics 2013; 6: S4.
73. Nijman SM, Friend SH. Cancer. Potential of the synthetic lethality principle. Science 2013; 342: 809-811.
74. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 2011; 39: D691-D697.
75. Huret JL, Ahmad M, Arsaban M, Bernheim A, Cigna J, Desangles F et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Res 2013; 41: D920-D924.
76. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M et al. GeneCards Version 3: the human gene integrator. Database (Oxford) 2010; 2010: baq020.
77. Hoffmann R. A wiki for the life sciences where authorship matters. Nat Genet 2008; 40: 1047-1051.
78. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S et al. Human Protein Reference Database-2009 update. Nucleic Acids Res 2009; 37: D767-D772.
79. Bullard JH, Purdom E, Hansen KD, Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinformatics 2010; 11: 94.
80. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.